Literature DB >> 8323028

Methodological aspects on separation and reaction conditions of bone and liver alkaline phosphatase isoform analysis by high-performance liquid chromatography.

P Magnusson1, O Löfman, L Larsson.   

Abstract

Some methodological aspects and characteristics on analysis of bone and liver alkaline phosphatase (EC 3.1.3.1, ALP) isoforms by high-performance liquid chromatography (HPLC) methods are presented. Factors affecting separation (analytical column type, column temperature, mobile phase buffer, mobile phase salt, gradient elution, flow rate) and reaction conditions (substrate type, substrate concentration, fluorescent substrates, substrate buffer type, substrate buffer concentration, substrate pH, substrate activators, substrate detergent, substrate flow rate, reaction temperature, postcolumn reaction detection) are discussed. Six peaks with ALP activity were separated and quantified by our new HPLC method in normal adult nonplacental serum: one intestinal/bone, two bone, and three liver ALP isoforms. Differences between the six ALP isoforms with respect to diethanolamine buffer concentration and substrate pH were observed. Although our HPLC method offers an improved possibility to clarify the reason for an increased total ALP in the routine clinical chemistry laboratory further research is needed to clarify the cellular origins of the different bone and liver ALP isoforms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323028     DOI: 10.1006/abio.1993.1247

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Glycosylation differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms.

Authors:  Cecilia Halling Linder; Sonoko Narisawa; José Luis Millán; Per Magnusson
Journal:  Bone       Date:  2009-07-22       Impact factor: 4.398

2.  Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.

Authors:  Mathias Haarhaus; Marie-Claude Monier-Faugere; Per Magnusson; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2015-04-02       Impact factor: 8.860

Review 3.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

4.  Isozyme profile and tissue-origin of alkaline phosphatases in mouse serum.

Authors:  Cecilia Halling Linder; Ulrika H Englund; Sonoko Narisawa; José Luis Millán; Per Magnusson
Journal:  Bone       Date:  2013-01-10       Impact factor: 4.398

5.  The novel bone alkaline phosphatase B1x isoform in children with kidney disease.

Authors:  Diana Swolin-Eide; Sverker Hansson; Lasse Larsson; Per Magnusson
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

6.  The Novel Bone Alkaline Phosphatase Isoform B1x Is Associated with Improved 5-Year Survival in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Anders Fernström; Abdul Rashid Qureshi; Per Magnusson
Journal:  Nutrients       Date:  2021-12-09       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.